India Glycols Ennature Biopharma Business Update

Revenue: Rs 246 Crore | EBITDA: Rs 29 Crore

Reader Takeaway: Growth is centered on high-margin nutraceuticals while maintaining a stable, cash-generative plant-based API business segment.

What just happened

India Glycols has released a performance overview for its Ennature Biopharma platform for FY26. The platform generated Rs 246 crore in revenue with an EBITDA of Rs 29 crore, representing an EBITDA margin of 11.9%. The business maintains a gross margin of 40.1% as it navigates the natural health and wellness sector.

Business Segments

The Ennature Biopharma platform operates through three distinct pillars:

• Plant-based APIs: Contributing 67% of sales, this segment is the primary cash generator, featuring products like Thiocolchicoside and Nicotine.
• Biopolymers: Accounting for 16% of sales, focusing on Guar Gum and specialty derivatives.
• Nutraceuticals: Representing 17% of sales, this is identified as the strategic growth engine, incorporating branded ingredients and CDMO services.

Strategic Growth Outlook

The company has set clear goals for each division. In the API segment, the plan is to launch one new product annually and increase market share in Nicotine Replacement Therapy. For biopolymers, the focus is shifting to higher-value food ingredients. Nutraceuticals will scale through increased clinical validation and expanded distribution across US, European, and Asian markets.

Manufacturing and Infrastructure

Operations are supported by manufacturing units in Dehradun (1,600 MT capacity) and Kashipur (24,000 MT capacity). The facilities hold significant global certifications including US-FDA, EU-GMP, and NSF-GMP to support exports into regulated markets.